RxDoctor Payments Data

Philip Adelman, MD

Neurology · Paoli, PANPI 1376594630

Payments from drug & device makers

$10,120in general payments, 2019–2025

Across 586 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$777
  • UCB, Inc.$767
  • Supernus Pharmaceuticals, Inc.$744
  • Neurocrine Biosciences, Inc.$722
  • Novartis$655
  • plus $5K from 45 others

What the payments were for

  • Speaking & faculty fees$1942%
  • Food & beverage$9,61695%
  • Education$3113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,120 in reported general payments places this provider in the 70th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$131,987
Medicare patients
758
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$187,306
CopaxoneGlatiramer Acetate26$150,227
VumerityDiroximel Fumarate11$99,442
NuplazidPimavanserin Tartrate15$67,178
Dalfampridine ErDalfampridine33$25,195
UbrelvyUbrogepant19$19,760
NuedextaDextromethorphan Hbr/Quinidine11$19,189
Emgality PenGalcanezumab-Gnlm27$18,385
Glatiramer Acetate13$17,982
QuliptaAtogepant16$17,583
Xtampza ErOxycodone Myristate13$16,164
Nurtec OdtRimegepant Sulfate13$15,985
Ajovy SyringeFremanezumab-Vfrm20$13,574
Carbamazepine ErCarbamazepine83$12,528
Levetiracetam ErLevetiracetam112$7,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$777$337,53439 claims
BiogenVumerity$576$99,44211 claims
Acadia Pharmaceuticals IncNuplazid$220$67,17815 claims
AbbVieUbrelvy, Qulipta$1,226$37,34335 claims
PfizerNurtec Odt, Dilantin$220$20,44728 claims
Avanir Pharmaceuticals, Inc.Nuedexta$101$19,18911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →